Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria (PRIORITY)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Steno Diabetes Center
Sponsor:
Collaborators:
Mosaiques Diagnostics GmbH
University Medical Centre Groningen
University of Glasgow
Istituto di Richerche Farmacologiche Mario Negri
Univerzita Karlova v Praze
Charite University, Berlin, Germany
Geniko Nosokomeio Athinas Ippokrateio
Institut Klinické a Experimentální Mediciny Praze
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Institut Universitaire de Recherche Clinique Montpellier
Klinikum St. Georg Leipzig
Universitaet Zürich
Cyril and Methodius University in Skopje
Hannover Clinical Trial Center
European Commission
Information provided by (Responsible Party):
Peter Rossing, Steno Diabetes Center
ClinicalTrials.gov Identifier:
NCT02040441
First received: December 16, 2013
Last updated: March 14, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)